|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar
|
|
2
|
Park JW, Chen M, Colombo M, Roberts LR,
Schwartz M, Chen PJ, Kudo M, Johnson P, Wagner S, Orsini LS, et al:
Global patterns of hepatocellular carcinoma management from
diagnosis to death: The BRIDGE Study. Liver Int. 35:2155–2166.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yoshimoto T, Imura S, Morine Y, Ikemoto T,
Arakawa Y, Iwahashi S, Saito YU, Takasu C, Ishikawa D, Teraoku H,
et al: The outcome of sorafenib therapy on unresectable
hepatocellular carcinoma: Experience of conversion and salvage
hepatectomy. Anticancer Res. 38:501–507. 2018.
|
|
5
|
Neuzillet C, de Mestier L, Rousseau B, Mir
O, Hebbar M, Kocher HM, Ruszniewski P and Tournigand C: Unravelling
the pharmacologic opportunities and future directions for targeted
therapies in gastro-intestinal cancers part 2: Neuroendocrine
tumours, hepatocellular carcinoma, and gastro-intestinal stromal
tumours. Pharmacol Ther. 181:49–75. 2018. View Article : Google Scholar
|
|
6
|
Yuan P, Cao W, Zang Q, Li G, Guo X and Fan
J: The HIF-2α- MALAT1-miR-216b axis regulates multi-drug resistance
of hepatocellular carcinoma cells via modulating autophagy. Biochem
Biophys Res Commun. 478:1067–1073. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang Li M, Ge L, Chen C, Fang L, Li T,
Tian H, Liu H, Chen J, Jiang TG, et al: An isocorydine derivative
(d-ICD) inhibits drug resistance by downregulating IGF2BP3
expression in hepatocellular carcinoma. Oncotarget. 6:25149–25160.
2015.PubMed/NCBI
|
|
8
|
Auyeung KK and Ko JK: Coptis chinensis
inhibits hepatocellular carcinoma cell growth through nonsteroidal
anti-inflammatory drug-activated gene activation. Int J Mol Med.
24:571–577. 2009.PubMed/NCBI
|
|
9
|
Liao J, Xu T, Zheng JX, Lin JM, Cai QY, Yu
DB and Peng J: Nitidine chloride inhibits hepatocellular carcinoma
cell growth in vivo through the suppression of the JAK1/STAT3
signaling pathway. Int J Mol Med. 32:79–84. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cazzamalli S, Corso AD and Neri D:
Targeted delivery of cytotoxic drugs: Challenges, opportunities and
new developments. Chimia (Aarau). 71:712–715. 2017. View Article : Google Scholar
|
|
11
|
Inoue T, Kurimoto N, Furuya N, Handa H,
Kida H, Nishine H, Ishida A, Nobuyama S, Mineshita M and Miyazawa
T: New technique for endobronchial ultrasound-guided transbronchial
needle aspiration to improve diagnostic yield. J Bronchology Interv
Pulmonol. 20:28–32. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Moukharskaya J and Verschraegen C:
Topoisomerase 1 inhibitors and cancer therapy. Hematol Oncol Clin
North Am. 26:507–525. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang N, Zhu M, Tsao SW, Man K, Zhang Z and
Feng Y: MiR-23a-mediated inhibition of topoisomerase 1 expression
potentiates cell response to etoposide in human hepatocellular
carcinoma. Mol Cancer. 12:1192013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Both J, Wu T, Ten Asbroek AL, Baas F and
Hulsebos TJ: Oncogenic properties of candidate oncogenes in
chromosome region 17p112p12 in human osteosarcoma. Cytogenet Genome
Res. 150:52–59. 2016. View Article : Google Scholar
|
|
15
|
Zhou Q, Abraham AD, Li L, Babalmorad A,
Bagby S, Arcaroli JJ, Hansen RJ, Valeriote FA, Gustafson DL,
Schaack J, et al: Topoisomerase IIα mediates TCF-dependent
epithelial-mesenchymal transition in colon cancer. Oncogene.
35:4990–4999. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Delgado JL, Hsieh CM, Chan NL and Hiasa H:
Topoisomerases as anticancer targets. Biochem J. 475:373–398. 2018.
View Article : Google Scholar
|
|
17
|
Russo P, Del Bufalo A and Cesario A:
Flavonoids acting on DNA topoisomerases: Recent advances and future
perspectives in cancer therapy. Curr Med Chem. 19:5287–5293. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kathiravan MK, Kale AN and Nilewar S:
Discovery and development of topoisomerase inhibitors as anticancer
agents. Mini Rev Med Chem. 16:1219–1229. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wasim L and Chopra M: Synergistic
anticancer effect of panobinostat and topoisomerase inhibitors
through ROS generation and intrinsic apoptotic pathway induction in
cervical cancer cells. Cell Oncol (Dordr). 41:201–212. 2018.
View Article : Google Scholar
|
|
20
|
Nukuzuma S, Nakamichi K, Kameoka M,
Sugiura S, Nukuzuma C, Tasaki T and Takegami T: Suppressive effect
of topoisomerase inhibitors on JC polyomavirus propagation in human
neuroblastoma cells. Microbiol Immunol. 60:253–260. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen J, Wang J, Lin L, He L, Wu Y, Zhang
L, Yi Z, Chen Y, Pang X and Liu M: Inhibition of STAT3 signaling
pathway by nitidine chloride suppressed the angiogenesis and growth
of human gastric cancer. Mol Cancer Ther. 11:277–287. 2012.
View Article : Google Scholar
|
|
22
|
Mou H, Guo P, Li X, Zhang C, Jiang J, Wang
L, Wang Q and Yuan Z: Nitidine chloride inhibited the expression of
S phase kinase-associated protein 2 in ovarian cancer cells. Cell
Cycle. 16:1366–1375. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sun M, Zhang N, Wang X, Li Y, Qi W, Zhang
H, Li Z and Yang Q: Hedgehog pathway is involved in nitidine
chloride induced inhibition of epithelial-mesenchymal transition
and cancer stem cells-like properties in breast cancer cells. Cell
Biosci. 6:442016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ou X, Lu Y, Liao L, Li D, Liu L, Liu H and
Xu H: Nitidine chloride induces apoptosis in human hepatocellular
carcinoma cells through a pathway involving p53, p21, Bax and
Bcl-2. Oncol Rep. 33:1264–1274. 2015. View Article : Google Scholar
|
|
25
|
Lin J, Shen A, Chen H, Liao J, Xu T, Liu
L, Lin J and Peng J: Nitidine chloride inhibits hepatic cancer
growth via modulation of multiple signaling pathways. BMC Cancer.
14:7292014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Makhey D, Gatto B, Yu C, Liu A, Liu LF and
LaVoie EJ: Coralyne and related compounds as mammalian
topoisomerase I and topoisomerase II poisons. Bioorg Med Chem.
4:781–791. 1996. View Article : Google Scholar
|
|
27
|
Prado S, Michel S, Tillequin F, Koch M,
Pfeiffer B, Pierré A, Léonce S, Colson P, Baldeyrou B, Lansiaux A,
et al: Synthesis and cytotoxic activity of benzo[c][1,7] and
[1,8]phenanthrolines analogues of nitidine and fagaronine. Bioorg
Med Chem. 12:3943–3953. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen G, Umelo IA, Lv S, Teugels E, Fostier
K, Kronenberger P, Dewaele A, Sadones J, Geers C and De Grève J:
miR-146a inhibits cell growth, cell migration and induces apoptosis
in non-small cell lung cancer cells. PLoS One. 8:pp. e603172013,
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Barrett T, Wilhite SE, Ledoux P,
Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH,
Sherman PM, Holko M, et al: NCBI GEO: Archive for functional
genomics data sets - update. Nucleic Acids Res. 41:D991–D995. 2013.
View Article : Google Scholar
|
|
30
|
Rhodes DR, Yu J, Shanker K, Deshpande N,
Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM:
ONCOMINE: A cancer microarray database and integrated data-mining
platform. Neoplasia. 6:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kolesnikov N, Hastings E, Keays M,
Melnichuk O, Tang YA, Williams E, Dylag M, Kurbatova N, Brandizi M,
Burdett T, et al: ArrayExpress update - simplifying data
submissions. Nucleic Acids Res. 43:D1113–D1116. 2015. View Article : Google Scholar
|
|
32
|
Deng M, Brägelmann J, Schultze JL and
Perner S: Web-TCGA: An online platform for integrated analysis of
molecular cancer data sets. BMC Bioinformatics. 17:722016.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBio- Portal. Sci Signal. 6:pl12013. View Article : Google Scholar
|
|
34
|
Fagerberg L, Lindskog C, Oksvold P,
Mardinoglu A, Sivertsson Å, Kampf C, Sjöstedt E, Asplund A, et al:
Proteomics. Tissue-based map of the human proteome. Science.
347:12604192015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Huang W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar
|
|
36
|
Burley SK, Berman HM, Christie C, Duarte
JM, Feng Z, Westbrook J, Young J and Zardecki C: RCSB Protein Data
Bank: Sustaining a living digital data resource that enables
breakthroughs in scientific research and biomedical education.
Protein Sci. 27:316–330. 2018. View Article : Google Scholar
|
|
37
|
Gao J, Liang L, Zhu Y, Qiu S, Wang T and
Zhang L: Ligand and structure-based approaches for the
identification of peptide deformylase inhibitors as antibacterial
drugs. Int J Mol Sci. 17:172016. View Article : Google Scholar
|
|
38
|
Orabi KY, Abaza MS, El Sayed KA, Elnagar
AY, Al-Attiyah R and Guleri RP: Selective growth inhibition of
human malignant melanoma cells by syringic acid-derived proteasome
inhibitors. Cancer Cell Int. 13:822013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
He HZ, Wang N, Zhang J, Zheng L and Zhang
YM: Tas13D inhibits growth of SMMC-7721 cell via suppression VEGF
and EGF expression. Asian Pac J Cancer Prev. 13:2009–2014. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wurmbach E, Chen YB, Khitrov G, Zhang W,
Roayaie S, Schwartz M, Fiel I, Thung S, Mazzaferro V, Bruix J, et
al: Genome-wide molecular profiles of HCV-induced dysplasia and
hepatocellular carcinoma. Hepatology. 45:938–947. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Mas VR, Maluf DG, Archer KJ, Yanek K, Kong
X, Kulik L, Freise CE, Olthoff KM, Ghobrial RM, McIver P, et al:
Genes involved in viral carcinogenesis and tumor initiation in
hepatitis C virus-induced hepatocellular carcinoma. Mol Med.
15:85–94. 2009. View Article : Google Scholar
|
|
42
|
Satow R, Shitashige M, Kanai Y, Takeshita
F, Ojima H, Jigami T, Honda K, Kosuge T, Ochiya T, Hirohashi S, et
al: Combined functional genome survey of therapeutic targets for
hepatocellular carcinoma. Clin Cancer Res. 16:2518–2528. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Roessler S, Jia HL, Budhu A, Forgues M, Ye
QH, Lee JS, Thorgeirsson SS, Sun Z, Tang ZY, Qin LX, et al: A
unique metastasis gene signature enables prediction of tumor
relapse in early-stage hepatocellular carcinoma patients. Cancer
Res. 70:10202–10212. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lim HY, Sohn I, Deng S, Lee J, Jung SH,
Mao M, Xu J, Wang K, Shi S, Joh JW, et al: Prediction of
disease-free survival in hepatocellular carcinoma by gene
expression profiling. Ann Surg Oncol. 20:3747–3753. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Neumann O, Kesselmeier M, Geffers R,
Pellegrino R, Radlwimmer B, Hoffmann K, Ehemann V, Schemmer P,
Schirmacher P, Lorenzo Bermejo J, et al: Methylome analysis and
integrative profiling of human HCCs identify novel protumorigenic
factors. Hepatology. 56:1817–1827. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kim JH, Sohn BH, Lee HS, Kim SB, Yoo JE,
Park YY, Jeong W, Lee SS, Park ES, Kaseb A, et al: Genomic
predictors for recurrence patterns of hepatocellular carcinoma:
Model derivation and validation. PLoS Med. 11:pp. e10017702014,
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Villa E, Critelli R, Lei B, Marzocchi G,
Cammà C, Giannelli G, Pontisso P, Cabibbo G, Enea M, Colopi S, et
al: Neoangiogenesis- related genes are hallmarks of fast-growing
hepatocellular carcinomas and worst survival. Results from a
prospective study. Gut. 65:861–869. 2016. View Article : Google Scholar
|
|
48
|
Melis M, Diaz G, Kleiner DE, Zamboni F,
Kabat J, Lai J, Mogavero G, Tice A, Engle RE, Becker S, et al:
Viral expression and molecular profiling in liver tissue versus
microdissected hepatocytes in hepatitis B virus-associated
hepatocellular carcinoma. J Transl Med. 12:2302014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Schulze K, Imbeaud S, Letouzé E,
Alexandrov LB, Calderaro J, Rebouissou S, Couchy G, Meiller C,
Shinde J, Soysouvanh F, et al: Exome sequencing of hepatocellular
carcinomas identifies new mutational signatures and potential
therapeutic targets. Nat Genet. 47:505–511. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Mah WC, Thurnherr T, Chow PK, Chung AY,
Ooi LL, Toh HC, Teh BT, Saunthararajah Y and Lee CG: Methylation
profiles reveal distinct subgroup of hepatocellular carcinoma
patients with poor prognosis. PLoS One. 9:pp. e1041582014,
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wang YH, Cheng TY, Chen TY, Chang KM,
Chuang VP and Kao KJ: Plasmalemmal Vesicle Associated Protein
(PLVAP) as a therapeutic target for treatment of hepatocellular
carcinoma. BMC Cancer. 14:8152014. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Makowska Z, Boldanova T, Adametz D,
Quagliata L, Vogt JE, Dill MT, Matter MS, Roth V, Terracciano L and
Heim MH: Gene expression analysis of biopsy samples reveals
critical limitations of transcriptome-based molecular
classifications of hepatocellular carcinoma. J Pathol Clin Res.
2:80–92. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wijetunga NA, Pascual M, Tozour J,
Delahaye F, Alani M, Adeyeye M, Wolkoff AW, Verma A and Greally JM:
A pre-neoplastic epigenetic field defect in HCV-infected liver at
transcription factor binding sites and polycomb targets. Oncogene.
36:2030–2044. 2017. View Article : Google Scholar :
|
|
54
|
Grinchuk OV, Yenamandra SP, Iyer R, Singh
M, Lee HK, Lim KH, Chow PK and Kuznetsov VA: Tumor-adjacent tissue
co-expression profile analysis reveals pro-oncogenic ribosomal gene
signature for prognosis of resectable hepatocellular carcinoma. Mol
Oncol. 12:89–113. 2018. View Article : Google Scholar
|
|
55
|
Cancer Cell Line Encyclopedia C: Genomics
of Drug Sensitivity in Cancer C: Pharmacogenomic agreement between
two cancer cell line data sets. Nature. 528:84–87. 2015.
|
|
56
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Aguirre-Gamboa R, Gomez-Rueda H,
Martínez-Ledesma E, Martínez-Torteya A, Chacolla-Huaringa R,
Rodriguez- Barrientos A, Tamez-Peña JG and Treviño V: SurvExpress:
An online biomarker validation tool and database for cancer gene
expression data using survival analysis. PLoS One. 8:pp.
e742502013, View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Wang JC: Cellular roles of DNA
topoisomerases: A molecular perspective. Nat Rev Mol Cell Biol.
3:430–440. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
59
|
Chhatriwala H, Jafri N and Salgia R: A
review of topoisomerase inhibition in lung cancer. Cancer Biol
Ther. 5:1600–1607. 2006. View Article : Google Scholar
|
|
60
|
Bush NG, Evans-Roberts K and Maxwell A:
DNA topoisomerases. Ecosal Plus. 6:62015. View Article : Google Scholar
|
|
61
|
Hou GX, Liu P, Yang J and Wen S: Mining
expression and prognosis of topoisomerase isoforms in
non-small-cell lung cancer by using Oncomine and Kaplan-Meier
plotter. PLoS One. 12:pp. e01745152017, View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Capranico G, Marinello J and Chillemi G:
Type I DNA topoisomerases. J Med Chem. 60:2169–2192. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Chen T, Sun Y, Ji P, Kopetz S and Zhang W:
Topoisomerase IIα in chromosome instability and personalized cancer
therapy. Oncogene. 34:4019–4031. 2015. View Article : Google Scholar
|
|
64
|
Ang C, Miura JT, Gamblin TC, He R, Xiu J,
Millis SZ, Gatalica Z, Reddy SK, Yee NS and Abou-Alfa GK:
Comprehensive multi- platform biomarker analysis of 350
hepatocellular carcinomas identifies potential novel therapeutic
options. J Surg Oncol. 113:55–61. 2016. View Article : Google Scholar
|
|
65
|
Wong N, Yeo W, Wong WL, Wong NL, Chan KY,
Mo FK, Koh J, Chan SL, Chan AT, Lai PB, et al: TOP2A overexpression
in hepatocellular carcinoma correlates with early age onset,
shorter patients survival and chemoresistance. Int J Cancer.
124:644–652. 2009. View Article : Google Scholar
|
|
66
|
Panvichian R, Tantiwetrueangdet A,
Angkathunyakul N and Leelaudomlipi S: TOP2A amplification and
overexpression in hepatocellular carcinoma tissues. BioMed Res Int.
2015.381602:2015.
|
|
67
|
Isaacs RJ, Davies SL, Sandri MI, Redwood
C, Wells NJ and Hickson ID: Physiological regulation of eukaryotic
topoisomerase II. Biochim Biophys Acta. 1400:121–137. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Srikantan S, Abdelmohsen K, Lee EK,
Tominaga K, Subaran SS, Kuwano Y, Kulshrestha R, Panchakshari R,
Kim HH, Yang X, et al: Translational control of TOP2A influences
doxorubicin efficacy. Mol Cell Biol. 31:3790–3801. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Calderwood SK: A critical role for
topoisomerase IIb and DNA double strand breaks in transcription.
Transcription. 7:75–83. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Szafran M, Skut P, Ditkowski B, Ginda K,
Chandra G, Zakrzewska-Czerwińska J, Jakimowicz D and Topoisomerase
I: Topoisomerase I (TopA) is recruited to ParB complexes and is
required for proper chromosome organization during Streptomyces
coelicolor sporulation. J Bacteriol. 195:4445–4455. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Li TK and Liu LF: Tumor cell death induced
by topoisomerase- targeting drugs. Annu Rev Pharmacol Toxicol.
41:53–77. 2001. View Article : Google Scholar
|
|
72
|
Hande KR: Clinical applications of
anticancer drugs targeted to topoisomerase II. Biochim Biophys
Acta. 1400:173–184. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Cort A and Ozben T: Natural product
modulators to overcome multidrug resistance in cancer. Nutr Cancer.
67:411–423. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Rodrigues T, Sieglitz F and Bernardes GJ:
Natural product modulators of transient receptor potential (TRP)
channels as potential anti-cancer agents. Chem Soc Rev.
45:6130–6137. 2016. View Article : Google Scholar : PubMed/NCBI
|
